Forte Biosciences FBRX Balance Sheet (2016-2026)

NASDAQ FBRX
$76.99 +0.00 (+0.00%)
At close: Aug 28, 2026 · 4:00 PM EDT
Reported Financials

Forte Biosciences Quarterly Balance Sheet

Periods 42 quarters
Latest Jun 2026

Forte Biosciences reported total assets of $205.74M and total liabilities of $21.95M for the quarter ended Jun 2026, up 90.9% year over year. This balance sheet covers 42 quarters of results from Mar 2016 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Balance Sheet Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Assets
Current Assets
Cash & EquivalentsCash & Equiv.
45.70M42.04M40.03M38.55M44.05M41.10M35.90M20.44M46.20M37.12M30.44M24.50M16.40M22.24M45.90M106.14M93.41M76.96M58.22M198.50M
Short-term InvestmentsInvestments (Current)
9.99M36.12M148.83M
Cash & Current Investments
45.70M42.04M40.03M38.55M44.05M41.10M35.90M30.43M46.20M37.12M30.44M24.50M16.40M58.37M45.90M106.14M93.41M76.96M58.22M347.33M
Prepaid Assets
0.89M0.48M0.38M0.30M0.55M0.41M0.37M0.32M0.92M1.20M1.06M1.21M1.30M2.98M1.30M1.47M2.00M3.63M6.89M4.64M
Current Assets
46.56M42.52M40.41M38.85M44.59M41.51M36.27M30.75M47.10M38.33M31.50M25.71M17.67M61.35M47.16M107.62M95.41M80.59M65.11M203.10M
Non-Current Assets
Property, Plant & Equipment (Net)PP&E (Net)
0.03M0.10M0.11M0.11M0.10M0.09M0.08M0.12M0.11M0.15M0.13M0.11M0.09M
Long-Term Deferred Tax
Other Non-Current Assets
0.83M0.79M0.89M0.87M0.53M0.49M0.44M0.41M0.68M0.54M0.41M0.27M0.19M0.14M0.18M0.06M1.53M2.06M2.00M2.55M
Non-Current Assets
0.83M0.79M0.89M0.87M0.53M0.49M0.44M0.44M0.78M0.65M0.52M0.37M0.28M0.21M0.30M0.17M1.68M2.19M2.11M2.64M
Assets
47.39M43.31M41.30M39.72M45.13M42.00M36.71M31.18M47.88M38.98M32.02M26.08M17.95M61.56M47.46M107.78M97.09M82.78M67.22M205.74M
Liabilities
Current Liabilities
Accounts Payables
2.33M0.95M0.58M0.70M1.19M1.15M1.34M3.01M5.35M1.42M1.69M5.28M5.16M4.88M5.02M5.30M5.49M9.99M13.08M14.01M
Notes Payables
Payables
2.33M0.95M0.58M0.70M1.19M1.15M1.34M3.01M5.35M1.42M1.69M5.28M5.16M4.88M5.02M5.30M5.49M9.99M13.08M14.01M
Accumulated Expenses
1.41M0.81M0.68M0.81M1.10M2.03M2.42M3.29M2.12M2.24M1.65M3.84M3.42M4.20M4.01M3.87M7.50M10.76M10.56M6.28M
Other Accumulated Expenses
0.06M0.02M0.14M0.05M0.03M0.01M0.06M0.04M0.07M0.00M0.01M0.01M0.13M0.11M0.08M0.03M0.01M0.08M0.08M
Current Leases
Current Deferred Revenue
Total Current Liabilities
3.74M1.76M1.26M1.51M2.29M3.18M3.76M6.30M7.47M3.67M3.33M9.12M8.58M9.08M9.03M9.17M12.99M20.75M23.65M20.29M
Non-Current Liabilities
Non-Current Debt
Convertible Debt
Non-Current Deffered Revenue
Preferred Stock Liabilities
Operating Leases
Other Non-Current Liabilities
1.04M1.48M1.66M
Total Non-Current Liabilities
20.75M23.65M20.29M
Total Liabilities
3.74M1.76M1.26M1.51M2.29M3.18M3.76M6.30M7.47M3.67M3.33M9.12M8.58M9.08M9.03M9.17M12.99M21.79M25.12M21.95M
Shareholder's Equity
Total Debt
Common Equity
43.65M41.55M40.05M38.21M42.84M38.82M32.95M24.88M40.41M35.31M28.68M16.96M9.37M52.48M38.43M98.61M84.10M60.99M42.10M183.79M
Liabilities and Shareholders Equity
47.39M43.31M41.30M39.72M45.13M42.00M36.71M31.18M47.88M38.98M32.02M26.08M17.95M61.56M47.46M107.78M97.09M82.78M67.22M205.74M
Retained Earnings
-69.82M-73.17M-75.73M-78.80M-82.20M-87.04M-93.80M-102.70M-112.65M-118.52M-125.94M-138.50M-146.84M-154.00M-169.70M-180.90M-198.60M-223.37M-245.51M-268.84M
Treasury Shares